1. No category

ONC -130320-1 7/2013
Welcome to a scientific education
for young urologists on
Castrate-Resistant Prostate Cancer
Copenhagen
22-23 November
Bella Sky Comwell, Copenhagen
Per-Anders Abrahamsson
Jack Schalken
Jan-Erik Damber
Karol Axcrona
Peter Iversen
Mika Matikainen
Sten Nilsson
Henriette Lindberg
Anders Angelsen
Ulf Persson
Professor, MD, PhD
Department of Urology
Skåne University Hospital
Sweden
Vik ihop på mitten efter den prickade linjen med denna sidan utåt och tejpa ihop.
Professor, MD, PhD
Department of Urology
Sahlgrenska University Hospital
and Academy
Gothenburg, Sweden
Professor, MD
Department of Urology
Rigshospitalet, Copenhagen
Denmark
Frankeras ej
Astellas Pharma AB
betalar portot
Professor, MD, PhD
Department of Oncology
Karolinska Institutet
Stockholm, Sweden
Professor, MD, PhD
Dept of Cancer Research and
Molecular Medicine
Dept of Urological Surgery
St. Olavs Hospital
Trondheim, Norway
Astellas Pharma AB
SVARSPOST
Kundnummer 20 46 43 37
208 00 Malmö
Astellas Pharma AB | Box 21046 | 200 21 Malmö
Telefon 040-650 15 00 | Fax 040-650 15 01
info.se@astellas.com | www.astellas.se
Professor of Experimental Urology, PhD
Research Director Urology
Radboud University, Nijmegen,
Medical Center
The Netherlands
Consultant in Urology, MD, PhD
Department of Urology
The Norwegian Radium Hospital
Oslo University Hospital
Oslo, Norway
Adjunct Professor, MD, PhD
Department of Urology
Helsinki University Central Hospital
Helsinki, Finland
MD, PhD
Department of Oncology
Herlev Hospital, University of Copenhagen
Herlev, Denmark
Professor in Health Economics
at Lund University
CEO of IHE, The Swedish
Institute for Health Economics
Lund, Sweden
22
November
Chairman of day 1 Per-Anders Abrahamsson
09.00-9.30
Introduction
Faculty presentation
Background/rationale, purpose, objectives
Definition of CRPC
Per-Anders Abrahamsson
09.30-10.15
Biological aspects in prostate cancer progression
Karol Axcrona
10.15-10.45
Coffee break
10.45-11.45
Targeting the androgen receptor in CRPC
Overview of CRPC
Jack Schalken
We are in the middle of an exciting phase in the
development of treatment options for patients suffering
from metastatic castration-resistant prostate cancer.
Take this opportunity to update and advance your
knowledge of the management of patients suffering
from castration-resistant prostate cancer!
SVARSKORT
NORDIC CRPC CAMP, Copenhagen 22-23 november 2013
Welcome to a Scientific Education on
castration-resistant prostate cancer (CRPC)
Födelsedatum:_______________________________________________________________________
Copenhagen, 22-23 November 2013
Klinik:_______________________________________________________________________________
Tremendous advancements are being made in the treatments available
for patients suffering from metastatic castration-resistant prostate
cancer, and principles of modern treatments are being introduced also
for patients suffering from CRPC.
Adress:______________________________________________________________________________
Patients with advanced prostate cancer can look forward, with anticipation and confidence, to a variety of new treatment options and better
methods for determining which of the tumours identified will require
treatment in the coming years.
Telefonnr./Mobilnr:____________________________________________________________________
CRPC camp aims to provide attendees with the latest update and
advance their knowledge of all aspects of the management of patients
with CRPC.
Önskemål om avreseflygplats:__________________________________________________________
11.45-12.45Lunch
12.45-13.35
Cancer treatment and health economics – basics and insights
Ulf Persson
13.35-14.35
Clinical presentations of CRPC
Mika Matikainen
14.35-15.00
Coffee break
15.00-16.00
E pidemiology of CRPC
Jan-Erik Damber
16.00-16.15
Short break
16.15-17.30
Update on current and new treatment modalities
Peter Iversen
17.30-17.45
Closure
Per-Anders Abrahamsson
A scientific education on
Castrate-Resistant Prostate
Cancer (CRPC)
Optional arrival with dinner on the
evening of november 21.
Changes in programme may occur.
19.30
23
November
Bus departure to restaurant
The urology department is the natural basis of the treatment of urology patients. As the condition progresses, it is imperative that multidisciplinary collaboration is optimal.
08.45-09.00
Introduction day 2
Multidisciplinarity – why?
Peter Iversen
09.00-10.00
Multidisciplinary teamwork
Update on other modalities
Sten Nilsson & Henriette Lindberg
Coffee break
10.30-11.30 Management of complications
Anders Angelsen
12.15-13.00Lunch
PL
P
www.CR
C camp.com
: young
USER N A ME
: urologists
PA SSWORD
13.00-13.50
Sequencing treatments
Overview of new knowledge. How to treat.
Per-Anders Abrahamsson
13.50-14.50
National guidelines for CRPC
Jan-Erik Damber, Peter Iversen,
Anders Angelsen, Mika Matikainen
14.50-15.00
Postnr.:_____________________ Ort:_____________________________________________________
E-post för registrering:________________________________________________________________
Transport till och från flygplatsen, ange adress:___________________________________________
Övriga upplysningar (Allergi etc.): _______________________________________________________
Arbetsgivaren betalar deltagaravgiften (preliminärt SEK 2 900:- ex moms). Deltagaravgiften
motsvarar 50% av kostnaden för resa, hotell inkl. frukost samt gemensamma måltider.
Arbetsgivaren önskar stå för mer än 50 % av kostnaderna (ange hur mycket):
Per-Anders Abrahamsson
Professor, MD, PhD
Department of Urology
Skåne University Hospital
Malmö, Sweden
Peter Iversen
Professor, MD
Department of Urology
Rigshospitalet
Copenhagen, Denmark
Closure
Peter Iversen
Enligt avtal mellan Läkemedelsindustriföreningen och SKL ska deltagande godkännas av huvudmannen.
En kopia för kännedom skickas även till den lokala Läkemedelskommitén.
Information om överenskommelse om samverkansformer mellan läkemedelsföretag och medarbetare i den
offentliga hälso- och sjukvården finns på www.lif.se.
Jan-Erik Damber
Professor, MD, PhD
Department of Urology
Sahlgrenska University Hospital and Academy
Gothenburg, Sweden
Karol Axcrona
Consultant, MD, PhD
Department of Urology
Oslo universitetssykehus
The Norwegian Radium Hospital
Oslo, Norway
11.30-12.15
Multidisciplinary teamwork
Sten Nilsson, Henriette Lindberg & Anders Angelsen
E A SE V ISIT
Sjukhus:_____________________________________________________________________________
Chairman of day 2 Peter Iversen
08.30-08.45
Recap of day 1
Per-Anders Abrahamsson
10.00-10.30
In addition to lectures, emphasis will be placed on the exchange of
experience and sharing-best-practice between participants and some of
the top opinion leaders within the field of therapy.
Namn (som i pass):___________________________________________________________________
Huvudmans-/verksamhetsansvarigs godkännande:
Underskrift huvudman/verksamhetsansvarig
Mika Matikainen
Adjunct Professor, MD, PhD
Department of Urology
Helsinki University Central Hospital.
Helsinki, Finland
Sten Nilsson
Professor, MD, PhD
Department of Oncology.
Karolinska Institutet
Stockholm, Sweden
Henriette Lindberg
MD, PhD
Department of Oncology
Herlev Hospital, University of Copenhagen
Herlev, Denmark
Namnförtydligande
Anders Angelsen
Professor, MD, PhD
Dept of Cancer Research and Molecular Medicine
Dept of Urological Surgery
St. Olavs Hospital.
Trondheim, Norway
Ort/datum
Astellas Pharma AB, Box 21046, 200 21 Malmö. Telefon: 040-650 15 00. Fax: 040-650 15 01.
info.se@astellas.com. www.astellas.se.